Interest in the immune-checkpoint protein programmed death 1 (PD-1), in T lymphocytes, and its ligand (PD-L1), in lymphoma B cells, have increased in parallel to the remarkable clinical outcomes demonstrated with their blockade in a broad range of tumour types [1]. Here, CD274 is linked to neoplasm.